Compare INCR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | ASMB |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | INCR | ASMB |
|---|---|---|
| Price | $1.38 | $36.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 13.2K | ★ 124.4K |
| Earning Date | 10-08-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $72,158,312.00 | $37,191,000.00 |
| Revenue This Year | $69.54 | $42.01 |
| Revenue Next Year | $41.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $1.22 | $7.75 |
| 52 Week High | $1.79 | $39.71 |
| Indicator | INCR | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 57.82 |
| Support Level | $1.23 | $35.05 |
| Resistance Level | $1.38 | $38.82 |
| Average True Range (ATR) | 0.05 | 1.91 |
| MACD | 0.00 | -0.32 |
| Stochastic Oscillator | 41.26 | 42.70 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.